About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT03235765

Cancer Panel From Blood of Lung Cancer Patients

Molecular profiling of lung cancers using circulating tumor DNA (ctDNA) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making. This...

Lead sponsor: Seoul National University Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Seoul National University Hospital

Collaborators

MACROGEN

This study is comprised of two cohorts as below: Cohort A: inoperable, untreated, non-small cell lung cancer patients Cohort B: non-small cell lung cancer patients who are in the treatment with targeted agents including immune checkpoint inhibitors

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Provision of informed consent prior to any study specific procedures, sampling, and analyses
•Pathologically confirmed non-small cell lung cancer
•Male or female, aged at least 20 years
•Matches one of two criteria :
•1. Cohort A: Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
•2. Cohort B: Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.

Exclusion Criteria

•Any concurrent and/or other active malignancy that has required treatment within 3 years
•Patients with mixed small cell histology
•Life expectancy less than 3 months
•Insufficient tissue for NGS test

Related studies

RECRUITINGPhase 2

PALACE: Cemiplimab Trial According to ctDNA Levels

NCT06917573 · Non Small Cell Lung Cancer Metastatic, Lung Diseases, and more

Active Not RecruitingPhase 3

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

NCT03774732 · Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, and more

Active Not RecruitingPhase 2

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NCT03808662 · TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, and more

Active Not RecruitingPhase 2

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

NCT05117242 · Non Small Cell Lung Cancer Metastatic

Active Not RecruitingPhase 1/2

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

NCT03907852 · Mesothelioma, Mesothelioma, Malignant, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 22, 2019Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment200

Start dateMar 2017

Last updatedJan 22, 2019

Condition

Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer Recurrent

Locations shown

Seoul National University Bundang Hospital

Seongnam

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 22, 2019Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions